IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Brian I. Rini, Tim Eisen, Romauld Zdrojowy et al.|The Lancet Oncology|2016

Cited by 218